NO20054744L - Behandling av Alzheimers sykdom - Google Patents

Behandling av Alzheimers sykdom

Info

Publication number
NO20054744L
NO20054744L NO20054744A NO20054744A NO20054744L NO 20054744 L NO20054744 L NO 20054744L NO 20054744 A NO20054744 A NO 20054744A NO 20054744 A NO20054744 A NO 20054744A NO 20054744 L NO20054744 L NO 20054744L
Authority
NO
Norway
Prior art keywords
disease
alzheimer
treatment
ifn
treat
Prior art date
Application number
NO20054744A
Other languages
English (en)
Norwegian (no)
Inventor
Luigi Grimaldi
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20054744L publication Critical patent/NO20054744L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20054744A 2003-03-19 2005-10-14 Behandling av Alzheimers sykdom NO20054744L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03100716 2003-03-19
PCT/EP2004/050316 WO2004082706A2 (fr) 2003-03-19 2004-03-17 Traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
NO20054744L true NO20054744L (no) 2005-10-14

Family

ID=33016977

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054744A NO20054744L (no) 2003-03-19 2005-10-14 Behandling av Alzheimers sykdom

Country Status (14)

Country Link
US (1) US20070110715A1 (fr)
EP (1) EP1620124A2 (fr)
JP (1) JP2006520368A (fr)
KR (1) KR20050115279A (fr)
CN (1) CN1791423A (fr)
AR (1) AR043660A1 (fr)
AU (1) AU2004222529A1 (fr)
BR (1) BRPI0408491A (fr)
CA (1) CA2516990A1 (fr)
EA (1) EA009668B1 (fr)
IL (1) IL170751A0 (fr)
MX (1) MXPA05009986A (fr)
NO (1) NO20054744L (fr)
WO (1) WO2004082706A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960781A (zh) * 2004-04-14 2007-05-09 沃尼尔·朗伯有限责任公司 治疗阿尔茨海默氏病的治疗组合
US7695911B2 (en) * 2005-10-26 2010-04-13 Celera Corporation Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
JP2009531323A (ja) * 2006-03-20 2009-09-03 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ アセチルコリンエステラーゼ阻害剤として有用な薬剤組成物
CN101116670B (zh) * 2006-08-01 2010-11-10 广州和竺生物科技有限公司 可提供活性甲基或参与甲基转移的化合物作为制备治疗病毒性疾病的药的应用
MX2009001937A (es) * 2006-08-21 2009-04-30 Novartis Ag Biomarcadores para el progreso de la enfermedad de alzheimer.
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
CN102209540A (zh) * 2008-11-11 2011-10-05 塔加西普特公司 使用α7-选择性配体的治疗方法
US20110081428A1 (en) * 2009-09-16 2011-04-07 The Buck Institute For Age Research Use of thioflavin-like compounds to increase life span and/or health span
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
CN102382096A (zh) * 2011-09-06 2012-03-21 清华大学 异香豆素及其衍生物的制备方法
CN102707065A (zh) * 2012-03-23 2012-10-03 常熟市虞山绿茶有限公司 Prohibitin蛋白抗体在制备诊断老年性痴呆的试剂盒中的应用
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
US9116974B2 (en) * 2013-03-15 2015-08-25 Robert Bosch Gmbh System and method for clustering data in input and output spaces
CN106754995B (zh) * 2016-11-25 2020-07-10 山东农业大学 中华蜜蜂AccCDK5基因及AccCDK5r1基因及其应用
RU2729391C2 (ru) * 2018-12-28 2020-08-06 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Моноклональное антитело, способное нейтрализовать биологическую активность интерферона бета-1а человека
CN109518211B (zh) * 2019-01-08 2020-11-06 合肥工业大学 一种芳香偶酰类化合物的电化学合成方法
WO2023080687A1 (fr) * 2021-11-03 2023-05-11 가천대학교 산학협력단 Procédé de criblage en masse à haute vitesse pour un médicament inhibiteur de multimère de bêta-amyloïde et composition comprenant de la doxorubicine ou un dérivé de celle-ci pour inhiber l'oligomérisation ou la fibrillation de bêta-amyloïde

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3768800A (en) * 1999-03-26 2000-10-16 Emil H. Franssen Treatment of brain changes with myelin protective agents
WO2001041782A2 (fr) * 1999-12-09 2001-06-14 Chiron Corporation Procede d'administration de cytokine aux systeme nerveux central et systeme lymphatique

Also Published As

Publication number Publication date
EP1620124A2 (fr) 2006-02-01
EA009668B1 (ru) 2008-02-28
MXPA05009986A (es) 2005-11-04
EA200501479A1 (ru) 2006-02-24
BRPI0408491A (pt) 2006-04-04
JP2006520368A (ja) 2006-09-07
WO2004082706A3 (fr) 2005-01-13
IL170751A0 (en) 2011-08-01
CA2516990A1 (fr) 2004-09-30
WO2004082706A2 (fr) 2004-09-30
AR043660A1 (es) 2005-08-03
AU2004222529A1 (en) 2004-09-30
KR20050115279A (ko) 2005-12-07
US20070110715A1 (en) 2007-05-17
CN1791423A (zh) 2006-06-21

Similar Documents

Publication Publication Date Title
NO20054744L (no) Behandling av Alzheimers sykdom
GB0223040D0 (en) Therapeutic compounds
ATE368031T1 (de) Neue gamma secretase inhibitoren
GB0225474D0 (en) Therapeutic agents
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
GB0223038D0 (en) Therapeutic compounds
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
ATE302753T1 (de) Sulfamide als gamma-secretase-inhibitoren
DE60330485D1 (de) Zur behandlung von diabetes
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
CY1108146T1 (el) ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ β-ΑΜΙΝΟ-ΕΤΕΡΟΚΥΚΛΙΚΗΣ-ΔΙΠΕΠΤΙΔΥΛΙΚΗΣ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗΝ ΑΓΩΓΗ Ή ΠΡΟΛΗΨΗ ΤΟΥ ΔΙΑΒΗΤΗ
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
MY139368A (en) Novel cyclohexyl sulphones
NO20053341D0 (no) Hindring og behandling av Alzheimers sykdom.
ATE519740T1 (de) Tetrahydroindolderivate zur behandlung von alzheimer-krankheit
DK0707477T3 (da) Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application